Cutting-Edge Therapeutics Limited
Registered number: 10146338
Balance Sheet
as at 30 April 2024
Notes 2024 2023
£ £
Fixed assets
Tangible assets 3 5,847 7,308
Current assets
Debtors 4 1,706 -
Investments held as current assets 5,846 5,846
Cash at bank and in hand 979 31,811
8,531 37,657
Creditors: amounts falling due within one year 5 (52,023) (25,797)
Net current (liabilities)/assets (43,492) 11,860
Net (liabilities)/assets (37,645) 19,168
Capital and reserves
Called up share capital 100 100
Profit and loss account (37,745) 19,068
Shareholders' funds (37,645) 19,168
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Zahid Sattar
Director
Approved by the board on 20 January 2025
Cutting-Edge Therapeutics Limited
Notes to the Accounts
for the year ended 30 April 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Fixtures, fittings, tools and equipment 20% reducing balance
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs.
Functional and presentation currency
The financial statements of the company are measured and presented in the currency of the primary economic environment in which the company operates, the functional currency. The financial statements are presented in Pound sterling (£), which is the company’s functional currency.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
Employee benefits
Short-term employee benefits
Short-term employee benefits are recognised as an expense in the period in which they are incurred.

Post-employment defined contribution plans
Amounts in respect of defined contributions plans are recognised as an expense as they are incurred.

Termination benefits
Provisions for termination benefits are recognised only when the company is demonstrably committed to terminate the employment of an employee or of a group of employees before their normal retirement date or to provide termination benefits as a result of an offer made in order to encourage voluntary redundancy.
Going concern
The financial statements have been prepared on the basis that the company will receive continued financial support from bank and director and has adequate resources to continue in operational existence for the foreseeable future.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 2 2
3 Tangible fixed assets
Fixtures, fittings, tools and equipment
£
Cost
At 1 May 2023 11,522
At 30 April 2024 11,522
Depreciation
At 1 May 2023 4,214
Charge for the year 1,461
At 30 April 2024 5,675
Net book value
At 30 April 2024 5,847
At 30 April 2023 7,308
4 Debtors 2024 2023
£ £
Other debtors 1,706 -
5 Creditors: amounts falling due within one year 2024 2023
£ £
Trade creditors 350 11,414
Corporation tax - 12,902
Other taxes and social security costs - 732
Other creditors 51,673 749
52,023 25,797
6 Related party transactions
Included within other creditors is director's loan of £26,923. The director and his wife are the only related parties. They have taken salaries and dividends which are disclosed in the accounts.
7 Controlling party
The director does not consider there to be an ultimate controlling party.
8 Other information
Cutting-Edge Therapeutics Limited is a private company limited by shares and incorporated in England. Its registered office is:
Suite 4, Cranbrook House
61 Cranbrook Road
Ilford
Essex
IG1 4PG
Cutting-Edge Therapeutics Limited 10146338 false 2023-05-01 2024-04-30 2024-04-30 VT Final Accounts April 2024 Zahid Sattar No description of principal activity 10146338 2022-05-01 2023-04-30 10146338 core:WithinOneYear 2023-04-30 10146338 core:ShareCapital 2023-04-30 10146338 core:RetainedEarningsAccumulatedLosses 2023-04-30 10146338 2023-05-01 2024-04-30 10146338 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 10146338 bus:AuditExempt-NoAccountantsReport 2023-05-01 2024-04-30 10146338 bus:Director40 2023-05-01 2024-04-30 10146338 1 2023-05-01 2024-04-30 10146338 2 2023-05-01 2024-04-30 10146338 core:PlantMachinery 2023-05-01 2024-04-30 10146338 countries:England 2023-05-01 2024-04-30 10146338 bus:FRS102 2023-05-01 2024-04-30 10146338 bus:FilletedAccounts 2023-05-01 2024-04-30 10146338 2024-04-30 10146338 core:WithinOneYear 2024-04-30 10146338 core:ShareCapital 2024-04-30 10146338 core:RetainedEarningsAccumulatedLosses 2024-04-30 10146338 core:PlantMachinery 2024-04-30 10146338 2023-04-30 10146338 core:PlantMachinery 2023-04-30 iso4217:GBP xbrli:pure